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Abstract: This paper explores the role of patient panels for shaping research for health, scientific 
research about health and illness, and applied medical research. After examining the history 
and purposes of involving patients in discussions and decision making for research, it outlines 
the expertise and skills required if panels are to be successful. The paper also analyses existing 
guidance for panels that include patients. Panels benefit from the experiential knowledge of 
panel members, craft knowledge of panel facilitators, and organizational knowledge gained 
through previous experience of hosting panels. Guidance is available that addresses structures 
and resources (for panel funders) and interpersonal communication and group dynamics (for 
panel members and facilitators). This guidance is most comprehensive when it has itself been 
developed by all these types of stakeholders.
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Introduction
The broad definition of a “panel” is a “small group of people brought together to 
investigate or decide upon a particular matter.”1 Of central importance to such panels 
are the different kinds of people who work together and the expertise that they bring 
to inform discussion or decisions. Increasingly, panels advancing scientific knowledge 
about health and illness, and about medical research for treatments, are acknowledging 
the different kinds of expertise that usefully complement the experience and skills of 
researchers. Patients and their carers are experts in their own experience of health. 
Clinicians and other professionals can bring vital expertise that stems from their 
experience of practice; product developers and manufacturers likewise.
In scientific and medical research, the term “panel” is used in various ways. The 
term “expert panel” is often used when people are brought together to discuss or decide 
what scientific or medical research should be done, and how. Another kind of panel 
exists where there is a less-explicit reference to expertise. Panels of potential customers, 
whether patients or clinicians, are long-established elements of market research within 
the pharmaceutical industry, similar to the customer “panels” in the commercial sector 
generally (for instance, for media and entertainment, panels of readers, listeners, or 
viewers). The purpose of market research panels is to collect and analyze information 
about people’s preferences and purchasing power and engage customers actively in 
reflecting on and discussing their interests and concerns. A second meaning is found 
in observational research where “panel data” refers to information collected from the 
same individuals, or from individuals in the same locations, over time with little or 
no reflection or debate by those being studied.
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These different types of panels constitute a spectrum 
of potential approaches to expertise, from panel members 
merely providing data at one end of the spectrum, through 
investigating and debating matters, to making decisions at 
the other end. How panels are constructed and what is asked 
of them depends on their specific purpose.
This paper explores all of the above issues, focusing in 
particular on the role that can be played by panels that include 
patients and wider publics. It identifies the opportunities 
within research projects, programs and governance systems 
for patients and other experts to bring their expertise to 
bear and the different reasons for this involvement. Using 
findings from a systematic review of public participation in 
agenda setting in research, it then examines the history of 
public panels, identifying both commercial and public sec-
tor origins. Panels are then distinguished in terms of their 
precise purpose: eliciting data, facilitating discussion, and 
sharing decisions. After considering the different kinds of 
knowledge, skills, and expertise that can be mobilized for 
panels, the paper reviews existing guidance on setting up 
and running patient panels, identifying differences in their 
emphasis and detail, and how this relates to the types of 
knowledge harnessed for their design.
Expert panels within science  
and medicine
Figure 1 illustrates a range of opportunities within England 
for experts to exert an influence before research is undertaken, 
while it is being undertaken, and after it is completed.
Each of these opportunities for experts to influence what 
or how research is conducted or used is an opportunity for 
patients to exert an influence too. As shown in the bottom row 
of Figure 1, research teams designing individual studies may 
reach out to other people with experience that complements 
their own, including experience of illness or of using health 
services or products, even at the stage of preparing funding 
applications. Indeed, some research programmers make this 
a requirement of funding in addition to the  requirement for 
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Figure 1 expert input into research systems, management, and practice.
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seeking approval from a research ethics committee, which 
also includes patient or public members.2 Once underway, 
studies may be guided by advisory groups that include 
patients, or patients may comment on data-collection meth-
ods and tools. Data monitoring committees that inspect 
interim data are essential to many trials but less likely to 
have patient members. Once complete, articles submitted to 
journals are peer reviewed, sometimes by patients.3
The middle row of Figure 1 represents funded studies that 
are conducted within research programs relying  heavily on 
expert panels to decide what research to commission and to 
judge the worth of studies proposed by researchers. Research 
programs may involve patients in these processes and set 
standards for patient involvement in individual studies. Like 
journals, funders maintain panels of experts for peer review-
ing research reports and these experts are sometimes patients. 
For instance, in England, the National Institute for Health 
Research (NIHR) Health Technology Assessment program 
includes patients in all these procedures.4
In turn, research programs work within national and 
international structures for research governance (top row of 
Figure 1). Whether considering the conduct of science or its 
use for public services, research policy is developed largely 
by politicians who, in a representative democracy, speak 
for the patients. In England they convene panels of mem-
bers of parliament, known as select committees, and invite 
witnesses to give evidence, including contributions from 
researchers and patients as external experts.5 Science policy 
is then implemented through universities to which the Higher 
Education Funding Council for England distributes public 
funds for research according to expert panels’ assessment of 
research excellence. These panels include members from the 
private, public, or third sectors with considerable expertise 
in commissioning, applying, or making use of research.6 
When it comes to using research findings, expert panels are 
also convened to develop policies to determine the use of 
medicines, devices, or clinical practices more widely. Patient 
involvement in panels for developing guidelines is not only 
widespread but also a widely accepted quality standard.7
The two empty cells in Figure 1 indicate the principle of 
independence in the conduct of science: although funders or 
policy makers may choose the research questions, it is not 
their place to influence the answers. Nevertheless, funders 
monitor the progress of studies they support. The Alzheimer’s 
Society even draws on its own panel of carers to conduct 
monitoring visits to ensure accountability to the funders (who 
in this case rely heavily on charitable giving from patients’ 
families and wills)8; involving carers reminds the researchers 
of the ultimate purpose and meaning of their work for people 
with Alzheimer’s disease and their families.
Why bring patients to expert panels?
Evidence-informed health services seek findings from 
research that employs methods to minimize bias and error, but 
this is of limited benefit if no thought is given to possible bias 
and misunderstandings inherent in the research questions. 
Drawing on their experience of health problems and health 
care provision, patients’ commentaries on research have 
focused on the choice of interventions attracting research 
attention and the choice of outcomes used to evaluate them. 
Cancer patients considered research about the management 
of practical, social, and emotional issues as a higher prior-
ity than investigating the biology or treatment of cancer.9 
Similarly, people suffering from osteoarthritis have called 
for more research about patient education when the research 
literature predominantly addresses oral drugs.10 Critiques 
have repeatedly noted: a lack of functional, social, and 
emotional outcomes; a lack of long-term outcomes (which 
require more effort to follow patients for a longer period of 
time); reliance on scales (often ratios or combinations of 
measures) that offer a quantitative assessment of effect that 
cannot be translated into a meaningful assessment of health; 
and little assessment of adverse reactions (often rare, so 
these only appear in large observational studies rather than 
small- or medium-sized trials).11,12 Policy makers who need 
to decide where to focus resources, when offered evidence 
of the effects of intervention, often also want to know not 
only whether something works but also whether it is better 
or worse than the alternatives and at what cost. Practitioners 
with responsibility for delivering complex interventions 
want to know not only what works but also how it works 
and what is needed to set it up. Finally, what is to be done 
in the absence of reliable evidence of effectiveness? Policy 
makers need to choose policies, practitioners have to set 
up and deliver interventions, and patients have to choose 
treatments, whether or not the research tells them what they 
want to know. Thus, judgments are made when deciding what 
research is to be done and how, and when using the findings. 
This raises questions about who the research belongs to. 
Who can judge appropriately what research is done – the 
people who do the research or the people well placed to use 
the findings?
There are two key arguments for involving a broad 
range of people in making judgments about doing and using 
research.13 First, as democracy expands from representative 
democracy alone to include participatory democracy, 
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involvement is increasingly “politically mandated” for people 
to have a say in decisions which affect them; this principle 
is supported by ethical arguments and enshrined in human 
rights. Second, involvement leads to better, more relevant 
decisions, helping to win support for change and facilitat-
ing the uptake of services. These arguments have led to the 
current situation where decisions about research are often 
made by researchers working together with people bringing 
other expertise.
Commercial origins of patient panels
When seeking examples internationally of patients or publics 
influencing research agendas, the earliest and most detailed 
examples were found in the commercial sector where they 
were convened to support the commercial development 
of devices to help disabled people lead more independent 
lives.14 A market research model that involved potential 
customers brought the “voice of the consumer” to every stage 
of development, engineering, and production and used one-
to-one interviews with customers to elicit experiences, with 
the reflection and creativity provided by multiple analysts 
reading interview transcripts. Although 20–30 interviews 
were required to identify 90%–95% of customer needs (and 
thus the research and development priorities), this may have 
been more cost-effective than focus groups with similar 
participants.15
Other commercial enterprises working in the same area 
raised the analytical power of the customers’ contribu-
tions either by their choice of customers or by developing 
questions to prompt more thoughtful customer responses. 
A Delphi study relied upon a hand-picked group of analyti-
cal and articulate long-term users of assistive devices with 
a variety of disabilities to provide “valuable insight into the 
evaluation factors used by one group of disabled persons 
whose members have given careful thought to how assistive 
devices should be designed, manufactured and selected.”16 
A similar consumer-responsive development process identi-
fied research and development priorities by involving power 
wheelchair users in brainstorming and five rounds of voting.17 
An alternative model for raising the analytical powers of 
product users was to invest more effort into the develop-
ment of probing questions to ask focus groups.18,19 Questions 
were developed by teams that typically included experts 
in the product (an engineer and a knowledgeable end user), 
the commercial context (a marketer) and research methods 
(the focus group facilitator and an expert in qualitative data 
analysis). Together they drew on personal experience, engi-
neering standards, consumer reports, academic research, 
market research, and industry and consumer interviews to 
write the questions. This effort led to three types of product 
requirements: (1) those that were assumed, often unspoken as 
they were too obvious to mention; (2) those that were impor-
tant day-to-day concerns; and (3) those that were exciting 
opportunities that could give a product a leading edge in the 
market place. Focus groups were followed by wider surveys 
to assess the importance of each requirement before deciding 
the direction of the research and development.
The enthusiasm amongst the research and development 
teams for hearing the “voice” of their customers was clear.15 
It gave them a “greater awareness of users’ feelings and 
perceptions.”17 Although portrayed very positively in these 
reports of engineering research, the authors of this study 
have not found such creative partnerships reported by the 
large commercial sector of the pharmaceutical industry – 
the reasons may be technical, commercial, or ethical. First, 
the intellectual gap between the social and biological aspects 
of medicines may be particularly challenging to bridge. 
Second, where pharmaceutical companies do bridge this gap, 
they may not wish to reveal a commercial advantage. Last, 
it may be because pharmaceutical companies are discour-
aged from approaching patients directly or attract criticism 
when they partner patient organizations. Pharmaceutical 
industry funding of patient groups raises doubts about their 
independence and reliability as patient advocates.20 Others 
argue that funding from pharmaceutical companies enables 
organizations to speak for patients more effectively whilst 
defending their independence.21 Despite these difficulties, 
market research with patients and clinicians is widespread 
on pharmaceutical company websites that encourage patient 
dialog and may well, as one site intends, accelerate real-world 
medical research.22
Public sector origins of patient panels
A consumer model for engaging patients transferred to 
the public sector in the 1980s when many countries priva-
tized state services and adopted market terminologies and 
management systems to those that remained in public 
ownership.23 This was supported by the Organization for 
Economic Co-operation and Development, which promoted 
a form of performance management in the public sector. 
For instance, market research and consumer satisfaction 
surveys were encouraged in the National Health Service 
(NHS)27 and the Citizen’s Charter portrayed users of pub-
lic services as customers with rights and choices through 
which they could influence the quality of the services they 
are offered.24,25
Patient Intelligence 2012:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5
Patient/public panels come to scientific and medical research
Although public sector involvement shares some of 
the same methods employed in the commercial sector (for 
instance, focus groups and interviews in the public sector 
revealing “what mattered to patients deeply influenced 
researchers’ thinking”),26 patients actively involved in 
influencing research frequently came from organizations 
that originated as part of the health advocacy movement 
of the 1970s and 1980s. In England, this included grow-
ing numbers of patient panels attached to general practices 
and the National Association for Patient Participation 
was founded in 1978; it continues to “promote the role 
of Patient Participation Groups as participants in decision 
making within the NHS.”27
As more explicit evidence-informed decision making 
for health care evolved in the 1980s, patient advocacy 
and campaigning groups focused their attention not only 
on health services, but also on the relevant (or in their 
eyes, sometimes, irrelevant) research conducted for health 
care.28 Patient involvement in deciding what research is 
done – setting research agendas – is now widespread. By the 
new millennium, policy documents reported involvement in 
setting agendas on a national and an international scale.14 At 
that time, patient or public panels were employed in Delphi 
surveys to set research priorities for peer review of research 
funding applications and at consensus conferences. Far more 
common than patient or public panels, however, was patient 
or public membership of panels that also included clinicians 
and researchers, with patients or members of the public being 
a small minority. This was the model adopted for agenda-
 setting panels for NHS research and development starting in 
the late 1990s. At that time there were very few formal studies 
of patients involved in prioritizing research,14 but a decade 
later a systematic review identified 27 formal  studies.29 
Patients are also involved in decisions about funding research 
teams, either “peer” reviewing research applications or shar-
ing the decisions as members of a funding panel.2
Purpose of panels: data, discussions, 
or decisions
Panels can be used to elicit patients’ ideas, facilitate patients’ 
discussion, and for decision making. Where people offer 
their own ideas alone, the theory of statistical sampling 
requires larger numbers to paint an unbiased picture of the 
wider population. Public opinion polls have long been used 
to gather opinions on biotechnology.30,31 Large numbers can 
also be accommodated by standing panels where members 
offer responses to a series of consultations, an arrangement 
employed by the Alzheimer’s Society when seeking carer 
views on research proposals.8 Smaller numbers are common 
when people speak for others, for instance, as respondents 
to public consultations or members of advisory groups 
being familiar with current debates through their affiliation 
with patient organizations. Without careful distinction of 
the different meanings of “representation,” these different 
approaches are sometimes confused. Large numbers of 
people may be chosen to present an image (represent) of 
a larger population, whereas small numbers of people are 
chosen with the knowledge and skills to (re)present the 
opinions of a wider group.
An ethnographic study of a panel of citizens, set in the 
context of the wider research literature, identified factors that 
support or challenge deliberation.25 Panels are not just for 
sharing fully formed ideas; rather, their value is in providing 
a “space” that is “legitimate” and “safe” in which people can 
share and develop their collective expertise. Whilst science 
is based on rational argument and scientists often consider 
emotional engagement with debates about science inap-
propriate, clear strong positions can polarize and clarify by 
engaging emotion as well as intellect. Engagement with a 
developing argument may be enhanced by strong opposing 
views expressed either by panel members or facilitators. 
Emotion and anecdote can be the “motivation to discuss, 
and to engage with, material and with fellow citizens.”25 
The Citizens’ Council encountered two barriers to engaging 
with arguments or developing collective expertise related 
to the principle of fairness. Formal procedures to ensure 
“fair” participation (speaking in order of request) and tacit 
rules (such as asking only one question each) sought the 
ideal of answering everyone’s questions rather than the goal 
of exploring issues in depth. The “unfairness” inherent in 
health inequalities prompted discomfort, conflict, and evasion 
as panel members struggled to discuss principles of social 
justice and cultural respect without implicating personal 
relationships and individual blame.25 Discussing sensitive 
topics with others requires particular skills for participants 
and facilitators.
A third purpose of panels is to make decisions. These panels 
are rarely comprised entirely of patients. It is far more common 
for patients to belong to panels with mixed membership; for 
instance, ethics committees, agenda setting panels, commission-
ing boards, or guideline development groups. The challenges 
encountered by the Citizens’ Council above are compounded 
when patients or members of the public deliberate with clini-
cians and researchers. This requires respect for different types 
of knowledge, relevant expertise and the skills to share that 
expertise, and willingness to learn from others.
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Knowledge, expertise, and skills
People with different perspectives and experience bring dif-
ferent types of knowledge. These have been characterized as: 
organizational knowledge that is gained by the experience 
of organizing services (eg, knowledge about governance and 
regulation); practitioner knowledge that is gained by the expe-
rience of professional practice (ie, practice skills); service 
user knowledge, gained from experience of and reflection 
upon services or situations; and policy knowledge, gained 
from the wider policy context.32
Bringing together in expert panels people with such 
different types of knowledge raises questions about the 
meaning of “expert.” Traditionally, theories about expertise 
have valued specialists whose knowledge is recognized by 
their qualifications or affiliation to a professional body: the 
“certified experts.”33 Experts may also be recognized for 
their specific skills or competencies or their ability to clearly 
frame and solve problems.34 Expertise that lies primarily in 
informal knowledge, derived from practice, participation, 
or experience in a particular field has been described as 
“experience-based expertise.”33 Experience-based experts 
have traditionally been excluded from knowledge sharing 
and decision making because their knowledge has been seen 
as inferior to certified expertise.
Observations of multidisciplinary working suggest that 
people who only acknowledge the model of expertise that 
values their own experience may be less open to ideas offered 
by people who are experts according to other models. People 
with a broad attitude to expertise who acknowledge the value 
in all the models discussed find it easier to see the value 
of others’ contributions and to work in multidisciplinary 
environments.35
These different attitudes to expertise were apparent from 
the framing of public consultations about bioethics.36 Some 
consultations were mounted with the aim of identifying “gaps 
in their knowledge and understanding in order to devise public 
education programs to remedy the deficits”; the researcher was 
the expert, applying structured methods focused on objective, 
measurable aspects of the topic and separating facts from 
values. Other consultations aimed to “uncover what the public 
knows and thinks about scientific developments and applica-
tions” in which the researcher was involved in the subject of 
study as a learner in order to produce new insights and under-
standing, employed open methods to elicit rich responses, and 
acknowledged that “facts” vary with context.
Discussions about expertise relate to the extent to 
which someone is valid as an expert in a given field. 
The UK organization INVOLVE refers to “non-researchers” 
as “members of the public,” which means that practically 
everyone can be an expert. Collins and Evans are far more 
specific in recognizing the boundaries of expertise within 
a given field.33 They argue that in the past “scientists were 
often attributed with authority to speak on subjects outside 
their narrow areas of specialization.”33 Instead, they argue, 
expertise is carried in the person of the contributor and, 
as such, certified and experience-based experts alike need 
to have in-depth knowledge of the topic to which they are 
contributing. This means that a dietician is not necessarily an 
expert on food policy, and a “member of the public” does not 
necessarily have the expertise to sit on a patients’ panel.
Considering scientists and nonscientists as having “pockets” 
of expert knowledge that they can contribute to science and 
other people as having expertise in interactional or facilitation 
skills has implications for whom to involve in decisions about 
science and public sector research. To consider which problems 
most deserve research, individuals must know something of a 
range of problems and understand the purpose of research. If 
a panel is convened for the purpose of discussion, they also 
need the skills to engage with these issues and discuss them 
with other people. Involving patients or the public makes this 
an exercise in participatory democracy. To improve research or 
the use of research, individuals need some expert understanding 
about specific problems and to understand the nature, potential, 
limitations, and options for research as well as the skills to 
engage with these issues and discuss them with other people. 
This is a collaborative activity of experts where each member 
of a panel brings their own background knowledge and skills 
for discussing research. Their engagement with the issues may 
be enhanced by increasing their knowledge before and during 
panel discussions with background papers and presentations. 
Their discussions may be enhanced by the use of facilitators 
who bring strong interactional skills for bridging their differ-
ent professional and personal worlds. Bringing these different 
worlds together is not merely an instrumental exercise requir-
ing some translation between different languages or spheres 
of expertise, but it can lead to emotional and dramatic group 
dynamics, an aspect of engagement that is rarely addressed in 
evaluations37 and is more easily accommodated with the help 
of a skilled independent facilitator.
Guidance for panels and involvement
Social research methodology provides sufficient guidance for 
panels where the purpose is to collect and analyze data from 
panel participants.38 Conventional committee procedures with 
agendas, speaking through the chair, voting, and minutes also 
have a history stretching back 1000 years through parliaments 
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and other democratic institutions.39–41 However, neither of 
these approaches adequately supports discussions and deci-
sions about research by or with patients and the public. Panels 
convened to discuss or make decisions about research need 
additional guidance that acknowledges the combination of 
technical and interpersonal elements of this work.
Tables 1 and 2 list a purposive sample of sources of advice 
for involving patients and the public in decisions about research 
and using the findings; these sources of advice vary in terms of 
their scope (being applicable to specific health conditions or 
health generally) and are all relevant to England as exercises 
that were national, European, or worldwide. Inspection of these 
sources of guidance revealed variations in their development: 
the extent to which the guidance is based on experiential 
knowledge, practice knowledge, organizational knowledge, 
and research knowledge; and whether consensus about the 
guidance was achieved formally or informally (Table 3).
Analyzing this range of advice according to the type of 
knowledge it rests on reveals three clusters of  documents (see 
Figure 2). One cluster consists of guidance that focuses on 
systematized knowledge; on methods for identifying evidence 
for clinical guidelines,7 for comparing burden of disease 
with lack of research,42 or for appraising descriptions of 
public involvement in research.43 All three tend to focus on 
structures, resources and procedures. Because the purpose 
of the Appraisal of Guidelines for Research and Evaluation 
II7 instrument is to appraise the quality of guidelines, only 
one of its six domains addresses “stakeholder involvement.” 
This domain considers whether professional stakeholders were 
panel members and whether the views and preferences of the 
target population (patients, public, etc) were sought; but nei-
ther question considers how well people were involved or their 
views or preferences sought. The World Health Organization 
methodology for setting research priorities includes a guiding 
principle of inclusivity to ensure as wide a participation as 
possible and stakeholder deliberation to allow for “equitable 
voice, constructive debate and conflict resolution” but offers 
little detail about how this can  happen.42 Although Wright 
et al had access to tacit knowledge through their experience 
of patient involvement as well as formalized knowledge, little 
tacit knowledge seems to have been retained during the devel-
opment of an instrument for critically appraising reports of 
patient or public involvement; the focus is more on structures 
and procedures than interpersonal communication.43
Another cluster rests on tacit knowledge, the experiential 
and practice knowledge or craft skills gained through direct 
experience of patient and public involvement.44,45 These are 
concerned less with the structure of panels and more with 
the procedures (such as the need for good information and 
training), practicalities, and interpersonal dynamics including 
respect for patient knowledge. INVOLVE guidance asserts 
the need for contributions to be respected, and includes a per-
son specification for public members that emphasizes clear 
communication and a receptive attitude.45 A tool kit provides 
advice from two facilitators familiar with the research about 
involvement based on their many years’ experience of patient 
and public involvement in health and research.44 This includes 
practical advice about seating arrangements, eye contact, 
language, tone, body language, active listening, nonverbal 
communication, and teleconference etiquette.
Between these two clusters is guidance based on both tacit 
knowledge and formalized knowledge. Development of the 
European League Against Rheumatism (EULAR) strategy 
began with a systematic review of active patient participation in 
research, followed by researchers, clinicians and patients familiar 
with collaborative working employing a Delphi method to agree 
eight recommendations for patient involvement.46 Although most 
of the eight EULAR recommendations focus on structures and 
procedures for patient involvement, two focus on interpersonal 
communication: on the “communication skills, motivation and 
constructive assertiveness” of the patient research partners and 
on the responsibilities of the principal investigator to “facilitate 
and encourage the contribution of patient research partners, 
Table 1 Application of advice for involving (and evaluating) 
patient membership of panels
Doing research Using  
research
Involving patients  
in panels
INvOLve45 
Telford et al48 
Cartwright and Crowe44 
The James Lind Alliance47 
world Health Organization42
eULAR49 
Cartwright et al44
Assessing patient  
involvement
wright et al43 
Telford et al48
AGRee II7*
Note: *Appraisal of Guidelines for Research and evaluation (AGRee) II was for 
assessing the quality of the process and reporting of clinical guideline development.
Abbreviation: eULAR, european League Against Rheumatism.
Table 2 Context for developing advice for involving (and evaluating) 
patient membership of panels
National International
Health condition specific wright et al (cancer)43 eULAR (arthritis)49
Generic health INvOLve45 
Cartwright and Crowe44 
The James Lind Alliance47 
Telford et al48
AGRee II7 
world Health 
Organization42
Abbreviations: AGRee, Appraisal of Guidelines for Research and evaluation; 
eULAR, european League Against Rheumatism.
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Patient/public panels come to scientific and medical research
and consider their specific needs.” These recommendations 
for patient involvement are complemented by the EULAR 
standardized operating procedures that offer additional points 
about presenting research information to panels.46 The James 
Lind Alliance Guidebook47 also draws on research knowledge 
about patient involvement in research and collaborative working, 
and on the practical experience of patients, clinicians, and 
facilitator. It similarly offers guidance on structures, procedures 
(including presenting research information to panels), and 
interpersonal communication; for the latter, it emphasizes 
how to manage different values and perspectives.
Conclusion
As part of the advocacy movement, patient and public panels 
for science and medicine have evolved from customer panels 
or population panels into expert panels that benefit from the 
reflective powers of patients who bring valuable direct experi-
ence of giving and receiving care. Panels with all-patient or 
public membership provide a forum for valuable debate but 
are distanced from the decision-making forum. Panels with a 
mix of patients or public and researchers risk marginalizing 
patient members who attend the forum, either because of their 
structures (minimum patient numbers) or because patient 
members lack support for working in an alien culture.
Comprehensive guidance that addresses structures and 
resources (for panel funders), processes (for panel hosts), and 
interpersonal communication and group dynamics (for panel 
members and facilitators) is available where panel members 
and panel facilitators have been involved in developing the 
guidance. Such guidance draws on the experiential knowl-
edge of panel members, craft knowledge of panel facilitators, 
and organizational knowledge accrued from hosting panels. 
Where the development or application of quality criteria are 
mediated by written reports (eg, critical appraisal guidelines 
or a systematic review), the focus is on structures and organi-
zational procedures. As with the evaluation of public involve-
ment,25,37 guidance for patient (membership of) scientific and 
medical panels is comprehensive only when it acknowledges 
the emotional and interpersonal aspects of collaborative work-
ing, as well as the intellectual, procedural, and structural.
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